Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Ilenia Calcaterra: Beyond Bleeding Control Emicizumab and the Evolution of Joint Health in Hemophilia A
Ilenia Calcaterra/LinkedIn
Sep 6, 2026, 12:12

Ilenia Calcaterra: Beyond Bleeding Control Emicizumab and the Evolution of Joint Health in Hemophilia A

Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Haemophilia, adding:

“Beyond bleeding control: what happens to joint health during emicizumab prophylaxis?

Pleased to share the results of the RESOLVE Study, now published in Haemophilia.

In this multicentre real-world study, we evaluated the longitudinal evolution of joint health in adults with severe haemophilia A after switching to emicizumab, combining clinical assessment with point-of-care ultrasound and HEAD-US.

After at least 2 years of prophylaxis, emicizumab was associated with a marked reduction in bleeding, with 76.9 percent of patients reporting zero joint bleeds.

But the most interesting finding came from the ultrasound assessment: among joints with hypertrophic synovium at baseline, 53.7 percent showed improvement or complete resolution.

At the same time, persistent synovial hypertrophy remained detectable in a relevant proportion of joints, particularly in the presence of pre-existing osteochondral damage.

As treatment efficacy continues to improve, our focus should increasingly move beyond ABR, integrating imaging-based surveillance, musculoskeletal assessment and individualized strategies aimed not only at preventing bleeding, but at preserving and whenever possible restoring joint health.

A great collaborative effort involving the haemophilia centres of Naples, Rome and Catanzaro”

Title: Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study

Authors: Matteo Nicola Dario Di Minno, Erminia Baldacci, Ilenia Lorenza Calcaterra, Guido D’Errico, Cristina Santoro, Alessandra Strangio, Silvia Sorella, Marzia Leotta, Rita Carlotta Santoro

Ilenia Calcaterra: Beyond Bleeding Control Emicizumab and the Evolution of Joint Health in Hemophilia A

Stay updated on all scientific advances with Hemostasis Today.

Alessandra Strangio bleeding disorders Clinical Research Cristina Santoro Emicizumab Erminia Baldacci Guido D'Errico haemophilia HEAD US Headlines Hematology Hemophilia A Hemophilic Arthropathy Hemostasis News Hemostasis Today Ilenia Calcaterra Ilenia Lorenza Calcaterra Joint Health Marzia Leotta Matteo Nicola Dario Di Minno Musculoskeletal Health Point Of Care Ultrasound Precision Medicine RESOLVE Study Rita Carlotta Santoro Silvia Sorella Synovial Hypertrophy
NewsFeed